{"count": 3, "results": [{"_id": "36475227", "pmid": 36475227, "pmcid": "PMC9717522", "title": "Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review", "journal": "Cureus", "authors": ["Chauhan D", "Memon F", "Patwardhan V", "Kotwani P", "Shah P", "Samala Venkata V"], "date": "2022-11-02T00:00:00Z", "doi": "10.7759/cureus.31007", "meta_date_publication": "2022 Nov", "meta_volume": "14", "meta_issue": "11", "meta_pages": "e31007", "score": 50289.7, "text_hl": "Combination therapy of statin with @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ is only indicated for severe @DISEASE_Hypercholesterolemia @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@ and very high-risk @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerotic cardiovascular disease@@@ (@<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@ASCVD@@@) population. ", "citations": {"NLM": "Chauhan D, Memon F, Patwardhan V, Kotwani P, Shah P, Samala Venkata V. Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review Cureus. 2022 Nov;14(11):e31007. PMID: 36475227", "BibTeX": "@article{36475227, title={Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review}, author={Chauhan D and Memon F and Patwardhan V and Kotwani P and Shah P and Samala Venkata V}, journal={Cureus}, volume={14}, number={11}, pages={e31007}}"}}, {"_id": "36040917", "pmid": 36040917, "pmcid": "PMC9426937", "title": "Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction", "journal": "PLoS One", "authors": ["Lotfollahi Z", "Mello APQ", "Fonseca FAH", "Machado LO", "Mathias AF", "Izar MC", "Damasceno NRT", "Oliveira CLP", "Neto AMF"], "date": "2022-08-30T00:00:00Z", "doi": "10.1371/journal.pone.0273292", "meta_date_publication": "2022", "meta_volume": "17", "meta_issue": "8", "meta_pages": "e0273292", "score": 50288.28, "text_hl": "...@<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Simvastatin/ezetimibe@@@ with either @CHEMICAL_Clopidogrel @CHEMICAL_MESH:D000077144 @@@clopidogrel@@@ or @CHEMICAL_Ticagrelor @CHEMICAL_MESH:D000077486 @@@ticagrelor@@@ was associated with less oxidized LDL, and @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@simvastatin/ezetimibe@@@ with @CHEMICAL_Ticagrelor @CHEMICAL_MESH:D000077486 @@@ticagrelor@@@ to lower @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@ content in the @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherogenic@@@ subfractions of LDL, while @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@ with @CHEMICAL_Ticagrelor @CHEMICAL_MESH:D000077486 @@@ticagrelor@@@ was the only combination associated with increase in LDL size.", "citations": {"NLM": "Lotfollahi Z, Mello APQ, Fonseca FAH, Machado LO, Mathias AF, Izar MC, Damasceno NRT, Oliveira CLP, Neto AMF. Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction PLoS One. 2022;17(8):e0273292. PMID: 36040917", "BibTeX": "@article{36040917, title={Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction}, author={Lotfollahi Z and Mello APQ and Fonseca FAH and Machado LO and Mathias AF and Izar MC and Damasceno NRT and Oliveira CLP and Neto AMF}, journal={PLoS One}, volume={17}, number={8}, pages={e0273292}}"}}, {"_id": "28437620", "pmid": 28437620, "title": "AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.", "journal": "Endocr Pract", "authors": ["Jellinger PS", "Handelsman Y", "Rosenblit PD", "Bloomgarden ZT", "Fonseca VA", "Garber AJ", "Grunberger G", "Guerin CK", "Bell DSH", "Mechanick JI", "Pessah-Pollack R", "Wyne K", "Smith D", "Brinton EA", "Fazio S", "Davidson M"], "date": "2017-04-01T00:00:00Z", "doi": "10.4158/EP171764.APPGL", "meta_date_publication": "2017 Apr", "meta_volume": "23", "meta_issue": "Suppl 2", "meta_pages": "1-87", "score": 50025.64, "text_hl": "ABBREVIATIONS: 4S = Scandinavian @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ Survival Study @VARIANT_c.1A>C_SPTB_human @VARIANT_tmVar:c|SUB|A|1|C;HGVS:c.1A>C;VariantGroup:0;CorrespondingGene:6710;CorrespondingSpecies:9606 @@@A1C@@@ = glycated hemoglobin AACE = American Association of Clinical Endocrinologists AAP = American Academy of Pediatrics ACC = American College of Cardiology ACE = American College of Endocrinology ACS = @DISEASE_Acute_Coronary_Syndrome @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ ADMIT = @DISEASE_Cerebral_Arterial_Diseases @DISEASE_MESH:D002539 @@@Arterial Disease@@@ Multiple Intervention Trial ADVENT = Assessment of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ Control and Evaluation of the Efficacy of Niaspan Trial AFCAPS/TexCAPS = Air Force/Texas @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@Coronary Atherosclerosis@@@ Prevention Study AHA = American Heart Association AHRQ = Agency for Healthcare Research and Quality AIM-HIGH = Atherothrombosis Intervention in @DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@Metabolic Syndrome@@@ With Low HDL/High @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@Triglycerides@@@ trial ASCVD = @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerotic cardiovascular disease@@@ ATP = Adult Treatment Panel apo = apolipoprotein BEL = best evidence level BIP = @CHEMICAL_Bezafibrate @CHEMICAL_MESH:D001629 @@@Bezafibrate@@@ Infarction Prevention trial BMI = body mass index CABG = coronary artery bypass graft CAC = @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@coronary artery calcification@@@ CARDS = Collaborative @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@Atorvastatin@@@ @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ Study CDP = Coronary Drug Project trial CI = confidence interval CIMT = carotid intimal media thickness @DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder @DISEASE_MESH:D012080 @@@CKD@@@ = @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@chronic kidney disease@@@ CPG(s) = clinical practice guideline(s) CRP = @GENE_CRP @GENE_1401 @@@C-reactive protein@@@ CTT = @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Treatment Trialists CV = cerebrovascular CVA = cerebrovascular accident EL = evidence level FH = @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ FIELD = Secondary Endpoints from the Fenofibrate Intervention and Event Lowering in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ trial FOURIER = Further Cardiovascular Outcomes Research with @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ Inhibition in Subjects With Elevated Risk trial HATS = HDL-@<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ Treatment Study HDL-C = high-density lipoprotein @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@ HeFH = heterozygous @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ HHS = Helsinki Heart Study @SPECIES_11676 @@@HIV@@@ = @SPECIES_12721 @@@human immunodeficiency virus@@@ HoFH = homozygous @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ HPS = Heart Protection Study HPS2-THRIVE = Treatment of HDL to Reduce the Incidence of Vascular Events trial HR = hazard ratio HRT = hormone replacement therapy hsCRP = high-sensitivity CRP IMPROVE-IT = Improved Reduction of Outcomes: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ Efficacy International Trial IRAS = @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@Insulin Resistance Atherosclerosis@@@ Study JUPITER = Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@Rosuvastatin@@@ LDL-C = low-density lipoprotein cholesterol Lp-PLA2 = lipoprotein-associated phospholipase A2 MACE = major cardiovascular events MESA = Multi-Ethnic Study of @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ MetS = @DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@metabolic syndrome@@@ MI = @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@myocardial infarction@@@ MRFIT = Multiple Risk Factor Intervention Trial NCEP = National @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Education Program NHLBI = National Heart, Lung, and Blood Institute @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@ = @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@polycystic ovary syndrome@@@ @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ = @GENE_PCSK9 @GENE_255738 @@@proprotein convertase subtilisin/kexin type 9@@@ Post CABG = Post Coronary Artery Bypass Graft trial PROSPER = Prospective Study of @CHEMICAL_Pravastatin @CHEMICAL_MESH:D017035 @@@Pravastatin@@@ in the Elderly at Risk trial QALY = quality-adjusted life-year ROC = receiver-operator characteristic SOC = standard of care SHARP = Study of Heart and Renal Protection T1DM = type 1 @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ mellitus T2DM = type 2 @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ mellitus TG = @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@triglycerides@@@ TNT = Treating to New Targets trial VA-HIT = Veterans Affairs High-Density Lipoprotein @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Intervention Trial VLDL-C = very low-density lipoprotein cholesterol WHI = @SPECIES_9606 @@@Women@@@'s Health Initiative.", "citations": {"NLM": "Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. PMID: 28437620", "BibTeX": "@article{28437620, title={AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.}, author={Jellinger PS and Handelsman Y and Rosenblit PD and Bloomgarden ZT and Fonseca VA and Garber AJ and Grunberger G and Guerin CK and Bell DSH and Mechanick JI and Pessah-Pollack R and Wyne K and Smith D and Brinton EA and Fazio S and Davidson M}, journal={Endocr Pract}, volume={23}, number={Suppl 2}, pages={1-87}}"}}]}